Stocks
Sarepta Therapeutics Financial Statements (SRPT) |
||||||||||
| Sarepta Therapeuticssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.05.2023 | 02.08.2023 | 01.11.2023 | 28.02.2024 | 01.05.2024 | 01.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 253.5 | 261.2 | 331.8 | 396.8 | 413.5 | 1 403 | |||
| Operating Income, bln rub | -138.1 | -133.5 | -20.8 | 24.6 | 34.9 | -94.8 | ||||
| EBITDA, bln rub | ? | -107.8 | -101.4 | 12.5 | -28.5 | 43.6 | -73.7 | |||
| Net profit, bln rub | ? | -516.8 | -23.9 | -40.9 | 45.7 | 36.1 | 16.9 | |||
| OCF, bln rub | ? | -209.4 | -122.2 | -114.7 | -54.7 | -242.1 | -533.7 | |||
| CAPEX, bln rub | ? | 9.49 | 17.9 | 40.9 | 19.0 | 32.4 | 110.3 | |||
| FCF, bln rub | ? | -218.9 | -140.1 | -155.6 | -73.7 | -274.5 | -644.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 356.6 | 360.6 | 315.6 | 328.0 | 321.5 | 1 326 | ||||
| Cost of production, bln rub | 35.0 | 34.1 | 37.0 | 44.2 | 50.6 | 165.9 | ||||
| R&D, bln rub | 245.7 | 241.9 | 194.3 | 195.5 | 194.4 | 826.1 | ||||
| Interest expenses, bln rub | 6.32 | 5.22 | 5.23 | 16.8 | 0.000 | 27.2 | ||||
| Assets, bln rub | 3 060 | 3 126 | 3 110 | 3 265 | 3 224 | 3 224 | ||||
| Net Assets, bln rub | ? | 712.7 | 741.4 | 764.4 | 859.3 | 961.2 | 961.2 | |||
| Debt, bln rub | 1 288 | 1 365 | 1 372 | 1 397 | 1 379 | 1 379 | ||||
| Cash, bln rub | 1 882 | 1 861 | 1 734 | 1 676 | 1 391 | 1 391 | ||||
| Net debt, bln rub | -593.9 | -496.0 | -362.0 | -279.4 | -11.4 | -11.4 | ||||
| Ordinary share price, rub | 137.8 | 114.5 | 121.2 | 96.4 | 129.5 | 78.0 | ||||
| Number of ordinary shares, mln | 88.2 | 88.7 | 88.9 | 93.6 | 94.0 | 94.0 | ||||
| Market cap, bln rub | 12 155 | 10 163 | 10 775 | 9 027 | 12 168 | 7 331 | ||||
| EV, bln rub | ? | 11 561 | 9 667 | 10 413 | 8 748 | 12 157 | 7 320 | |||
| Book value, bln rub | 706 | 723 | 745 | 830 | 961 | 961 | ||||
| EPS, rub | ? | -5.86 | -0.27 | -0.46 | 0.49 | 0.38 | 0.18 | |||
| FCF/share, rub | -2.48 | -1.58 | -1.75 | -0.79 | -2.92 | -6.85 | ||||
| BV/share, rub | 8.00 | 8.15 | 8.38 | 8.86 | 10.2 | 10.2 | ||||
| EBITDA margin, % | ? | -42.5% | -38.8% | 3.76% | -7.17% | 10.6% | -5.25% | |||
| Net margin, % | ? | -203.8% | -9.16% | -12.3% | 11.5% | 8.74% | 1.20% | |||
| FCF yield, % | ? | -3.85% | -5.24% | -5.71% | -6.52% | -5.29% | -8.78% | |||
| ROE, % | ? | -156.5% | -122.4% | -90.4% | -62.4% | 1.76% | 1.76% | |||
| ROA, % | ? | -36.4% | -29.0% | -22.2% | -16.4% | 0.52% | 0.52% | |||
| P/E | ? | -10.9 | -11.2 | -15.6 | -16.8 | 720.1 | 433.9 | |||
| P/FCF | -26.0 | -19.1 | -17.5 | -15.3 | -18.9 | -11.4 | ||||
| P/S | ? | 12.5 | 10.1 | 9.75 | 7.26 | 8.67 | 5.22 | |||
| P/BV | ? | 17.2 | 14.0 | 14.5 | 10.9 | 12.7 | 7.63 | |||
| EV/EBITDA | ? | -23.0 | -24.0 | -37.4 | -38.9 | -165.0 | -99.3 | |||
| Debt/EBITDA | 1.18 | 1.23 | 1.30 | 1.24 | 0.15 | 0.15 | ||||
| R&D/CAPEX, % | 2 590% | 1 351% | 474.9% | 1 027% | 599.0% | 748.9% | ||||
| CAPEX/Revenue, % | 3.74% | 6.86% | 12.3% | 4.80% | 7.85% | 7.86% | ||||
| Sarepta Therapeutics shareholders | ||||||||||
